Genus plc (GNS)

Price£24.12Cached quoteAs of 2026-11-04 12:36 UTC

AI: Fair-priced

Active animal-genetics business with improving profitabilityGenus plc remains an active animal-genetics business, with profitability improving despite lower reported revenue.

The latest preliminary results, published 10 September 2026 for the year ended 30 June 2026, report revenue of £658.1m, down 2%, principally reflecting PIC China deconsolidation. Adjusted profit before tax increased 35% to £100.2m; adjusted operating profit including joint ventures reached £116.0m. Genus plc is UK company 02972325 and operates PIC pig genetics and ABS cattle genetics.

Fair-priced after separating recurring and exceptional earningsImproved recurring earnings and lower debt support the valuation, while moderate growth and cyclicality limit clear upside.

Barclays' latest verified delayed quote is £21.34. Hargreaves Lansdown displays £1.42bn market capitalisation, a 19.49x P/E and 1.65% dividend yield; its P/E calculation basis is unspecified. Statutory profit before tax of £310.5m includes a £204.1m PIC China disposal gain. Adjusted EPS was 110.3p versus statutory EPS of 431.6p, making unadjusted earnings a poor guide to recurring value.

Stronger liquidity, but capital returns consume flexibilityDebt reduction improves resilience, although the buyback will use cash and disposal proceeds are non-recurring.

At 30 June 2026, net debt was £71.8m versus £228.2m a year earlier, covenant leverage was 0.4x and facility headroom was £263.8m. FY26 free cash flow was £62.0m; net disposal proceeds were £97.7m. Principal revolving facilities mature in June 2030. Management expects lower FY27 free cash flow. A 17 September market snapshot reported volume of 285,120 shares, which does not establish average liquidity or execution depth for larger orders.

Moderate growth outlook and conditional biotechnology upsideDisease-resistant pigs offer upside, but agricultural pressures and regulatory execution make future growth uncertain.

The comparison base is normalised FY26 adjusted profit before tax of £90.3m, not the £100.2m headline result. Pressures include North American pig disease, low Brazilian pork prices and subdued global dairy prices. PRRS-resistant-pig commercialisation is beginning in selected Latin American countries; approvals in Mexico, Japan and China remain pending. Regulatory delays, customer adoption, currency movements and execution of the China joint venture could constrain returns.

AI: News

Buyback launchedGenus launched a buyback of up to £60m and began purchases intended for cancellation.

Genus announced the programme alongside its FY26 results, with completion expected in the second half of FY27. The 14 September RNS reports 67,153 shares purchased through J.P. Morgan Securities during 10–11 September, intended for cancellation. The programme returns capital but reduces cash otherwise available for investment or protection against agricultural downturns.

Executive awards disclosedThe latest 17 September RNS concerned conditional incentive and deferred-bonus awards, not fresh trading guidance.

A separate 16 September announcement covered earlier incentive vesting and share sales to meet income-tax and social-security liabilities. These disclosures should not be mistaken for open-market confidence purchases or automatically treated as a bearish insider signal. Genus states that its FY26 annual report will be published in October; the September preliminary results remain the latest reported full-year results.

Loading local price history

Revenue

2022

2023

2024

2025

2026

Net income

2022

2023

2024

2025

2026

Free cash flow

2022

2023

2024

2025

2026

Total cash / debt

CashTotal debt

2022

2023

2024

2025

2026

Financial statements

	2026	2025	2024	2023	2022
Revenue	£658.1M	£672.8M	£668.8M	£689.7M	£593.4M
Research & development	N/A	N/A	£27.8M	£31.0M	£5.6M
Operating expenses	N/A	N/A	£147.7M	£143.5M	£96.5M
Operating income	£87.3M	£42.4M	£6.4M	£40.5M	£49.4M
Operating margin	13.27%	6.30%	0.96%	5.87%	8.32%
Net income	£285.5M	£19.3M	£2.4M	£31.8M	£36.7M
Net profit margin	43.38%	2.87%	0.36%	4.61%	6.18%
Basic EPSper basic share	£4.32	£0.29	£0.12	£0.51	£0.63
Diluted EPSper diluted share	£4.25	£0.29	£0.12	£0.51	£0.62

Review official source filings ↗

Owners

Reported major voting-rights holders

FCA threshold notices

5.00%of voting rights

JNE Partners LLPNotified Jun 11, 2026

View holders

Reported major voting-rights holders of GNS
Holder	Voting rights
JNE Partners LLP	5.00%Jun 11, 2026 · 3.33M votes
BlackRock, Inc.	5.00%Mar 9, 2026 · 3.33M votes
Baillie Gifford & Co	4.99%Oct 13, 2025 · 3.32M votes

These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.

Gray completes the 100% scale; it is not an estimate of other owners.

Source: FCA voting-rights notice ↗Updated Oct 21, 2026

Community posts

View community

@tickerstat1 month ago
Genus announces a £60 million buyback after stronger annual earnings
Genus ($GNS-LSE) announced a £60 million share-buyback program after adjusted pre-tax profit rose 35% to £100.2 million. Revenue declined 2% to £658.1 million, but stronger profitability in its pig-genetics business and improvements in its ...
0
0

Genus plc (GNS)

Financial charts

Financial statements

Owners

Community posts

Genus announces a £60 million buyback after stronger annual earnings